Investigational drug · Phase 3
APC101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for PHN - Post-Herpetic Neuritis.
Phase 3Last checked: Nov 19, 2026Latest source record: May 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "APC101"
First trial start
2026
Aug 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "APC101", any sponsor or status.
Conditions studied
As listed on its trial records.
- PHN - Post-Herpetic Neuritis
Largest trials
Live from ClinicalTrials.gov: studies naming "APC101" as an intervention, largest first.
- A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.Pivotal-lookingNot yet recruiting
Andros Pharmaceuticals Co., Ltd.Industry
NCT07599800 · 333 participants (planned) · Start Aug 1, 2026 · Primary completion Dec 31, 2028
Drug: APC101 · For: PHN - Post-Herpetic Neuritis
Sites: Florida City, Florida; Brisbane, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Intracellular sclerostin promotes tumor progression and metastasis as a potential therapeutic target in triple-negative breast cancer.
Sun M, Luo H, Qiao S, et al. · Cell Rep Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.